Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • All Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

Warning: foreach() argument must be of type array|object, null given in /var/www/wordpress/wp-content/themes/awaken-child/single-newsletter.php on line 54

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Clinical Trial
  4. /
  5. Phase II Randomized Study...

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

May 27, 2020checkorphan
Learn more about:
Giant cell myocarditis
Related Clinical Trial
Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Recruitment Information

Administrative Informations

Free Newsletter

Tools

Subscribe to our newsletter

Email Alerts

Rss Feeds

Print this page

Follow us on:

Related

  • Giant cell myocarditis
  • Myocarditis Foundation
  • Myocarditis Program at Mayo Clinic
More
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2023 CheckOrphan.
    Developed by: Gonza.io logo Powered by: Cloudscale logo